Almotriptan is an effective and well-tolerated treatment for migraine pain: Results of a randomized, double-blind, placebo-controlled clinical trial

Cephalalgia

Volumn 22, Issue 6, 2002, Pages 453-461

  Dowson, Andrew J ^a,e   Massiou, H ^b   Lainez J M ^c   Cabarrocas, X ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d Laboratorios Almirall SA ^*  (Spain)

^e Ludshott End   (United Kingdom)

Author keywords

Almotriptan; Efficacy; Migraine; Sumatriptan; Tolerability

Indexed keywords

ALMOTRIPTAN; PLACEBO; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; INDOLE DERIVATIVE; SEROTONIN AGONIST; TRYPTAMINE DERIVATIVE;

ADULT; ANALGESIA; ARTICLE; BACKACHE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE PAIN; MULTICENTER STUDY; PAIN; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SOMNOLENCE; THORAX DISEASE; VERTIGO; ADOLESCENT; AGED; COMPARATIVE STUDY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; MULTICENTER STUDIES; RECURRENCE; SEROTONIN AGONISTS; SUMATRIPTAN; TREATMENT OUTCOME; TRYPTAMINES;

EID: 0036632560     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2002.00394.x     Document Type: Article

References (24)

1. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin 1997; 15:1-13.
2. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999; 159:813-8.
3. Humphrey PPA, Feniuk W, Perren MJ, Beresford IJM, Skingle M. Serotonin and migraine. Ann NY Acad Sci 1990; 600:587-98.
4. Goadsby PJ. Serotonin receptors and the acute attack of migraine. Clin Neurosci 1998; 5:18-23.
5. Peroutka S. Serotonin receptor subtypes and neuropsychiatric diseases: focus on 5-HT1D and 5-HT3 receptor agents. Pharmacol Rev 1991; 43:579-86.
6. Dahlöf C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine - with regard to both efficacy and general well-being. Cephalalgia 1992; 125:214-20.
7. Dahlöf C, Björkman R. Diclofenac-K (50 and 100 mg) and placebo in acute treatment of migraine. Cephalalgia 1993; 13:117-23.
8. Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the acute treatment of migraine and cluster headaches. Drugs 1992; 43:776-98.
9. Perry CM, Markham A. Sumatriptan. An updated review of its use in migraine. Drugs 1998; 55:889-922.
10. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients. Cephalalgia 1996; 16:264-9.
11. Jansat JM, Costa J, Salvà P, Fernandez J, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. Br J Pharmacol 2002; in press.
12. Pascual J, Falk R, Docekal R, Prusinski A, Jelencsik J et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001; 45:206-13.
13. Cabarrocas X, Esbri R, Peris F, Ferrer P. Long-term efficacy and safety of oral almotriptan: interim analysis of a 1-year open study. Headache 2001; 41:57-62.
14. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal R et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20:588-96.
15. Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58:944-50.
16. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001; 41:449-55.
17. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalagia 1988; 8 (Suppl. 7):1-96.
18. Hauck WW, Anderson S. A comparison of large sample confidence interval methods for the difference of two binomial probabilities. The Am Statistician 1986; 40:318-22.
19. Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician's view. Cephalalgia 2000; 20 (Suppl. 2):14-24.
20. Kramer MS, Matzura-Wolfe D, Polis A, Getson A, Amaraneni PG et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51:773-81.
21. Klassen A, Elkind A, Ashgarnejad M, Webster C, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache 1997; 37:640-5.
22. Mathew NT, Asgharnejad M, Peykamian M, Laurenza A. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, crossover study. Neurology 1997; 49:1485-90.
23. Rapoport AM, Ramadan NM, Adelman JU, Mathew NT, Elkind AH, Kudrow DB et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49:1210-8.
24. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993; 13:238-44.